ArticleMicrobial cell factories2026
A versatile toolset for Staphylococcus aureus gene inactivation enables testing of anti-phage defense systems in native genetic backgrounds.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundFunctional gene analysis of Staphylococcus aureus across different strains requires the development of genetic engineering tools. In studies on phage therapy, such analysis is especially important for understanding the genomic differences between strains, underlying the differences in sensitivity to phages. Meanwhile, difficulties in introducing DNA constructs for genetic manipulations into non-laboratory S. aureus strains hinder the elucidation of staphylococcal anti-phage defense strategies.
resultsWe used a transducing S. aureus bacteriophage and an E. coli -S. aureus shuttle plasmid with a DNA fragment of this phage to develop a toolset for recombinational gene replacement in difficult-to-transform S. aureus isolates. The plasmid carried an erythromycin-resistance cassette flanked by unique restriction sites for cloning the flanking regions of target DNA to be replaced. Plasmid loss from recombinants with the desired gene replacement was achieved by removing the plasmid par gene, which is essential for plasmid inheritance. Recombinants that acquired the cassette but lost the plasmid were resistant to erythromycin and susceptible to chloramphenicol selective for plasmid backbone. We applied our system to inactivate the predicted anti-phage defense gene avs2 in a clinical S. aureus isolate and inactivated the identical gene in a laboratory strain. While the mutation sensitized the laboratory strain to three phages, it did not affect the clinical strain's sensitivity to phages, demonstrating the complexity of phage-bacterial interactions and limitations of bioinformatic phage susceptibility predictions without experimental validation. The large terminase subunits of Avs2-sensitive phages were predicted to form complexes with Avs2, suggesting their direct involvement in triggering Avs2.
conclusionsOur new, simple toolset for introducing plasmids carrying donor DNA for genetic manipulation into S. aureus strains that are difficult to transform proved suitable for generating chromosomal gene knockouts in clinical S. aureus isolates. Its use to knock out an exemplary anti-phage defense gene, avs2, in a clinical S. aureus strain and comparative phenotypic analysis of the obtained mutant with that of a laboratory strain revealed differences resulting presumably from different genomic backgrounds of target genes in each strain. This supports the validity of our approach and shows the importance of empirical phage sensitivity testing of strains in native backgrounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.